Inovio Pharmaceuticals (INO) PT Lowered to $8 at Roth Capital, Following Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.63 -1.81%
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Join SI Premium – FREE
Roth Capital analyst Jonathan Aschoff lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $8.00 (from $11.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Upgrades Inovio Pharmaceuticals (INO) to Buy
- SGHC Limited (SGHC) PT Lowered to $16 at StoneX
- Sprout Social Inc. (SPT) PT Raised to $15 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
